Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant (NASDAQ: CLGN) announced a collaboration with Tel Aviv University and Sheba Medical Center to co-develop a 'Gut-on-a-Chip' tissue model aimed at enhancing treatment for ulcerative colitis. The agreement entails that CollPlant will finance the development and secure exclusive rights for manufacturing and commercialization. This 3D bioprinted intestine model combines human recombinant collagen with innovative biomaterials, promising progress in personalized medicine and drug discovery while potentially reducing reliance on animal testing.
CollPlant (Nasdaq: CLGN) has launched Collink.3D™ 90, a recombinant human collagen-based bioink designed for versatile 3D bioprinting applications, including both soft and hard tissues. This product demonstrates increased mechanical properties and faster human cell migration compared to a widely used hydrogel. The introduction of this bioink aligns with the company's strategic goal to enhance its portfolio of rhCollagen-based bioinks for biopharma and academic markets, representing a significant expansion in the tissue engineering field.
CollPlant Biotechnologies (NASDAQ: CLGN), a leader in regenerative medicine, announced a presentation by Deputy CEO Eran Rotem at the Canaccord Genuity MedTech Forum on November 17, 2022, at 2:00 p.m. ET. The presentation will overview the company's innovative human-collagen based technologies aimed at tissue regeneration and organ manufacturing. CollPlant has established agreements with Allergan and 3D Systems for product development in dermal fillers and regenerative matrices. Attendees can request one-on-one meetings with the company during the event.
CollPlant Biotechnologies (Nasdaq: CLGN) will be presenting an overview at the Dawson James 7th Annual Small Cap Growth Conference in Jupiter, Florida. The presentation will be led by Deputy CEO & CFO Eran Rotem on October 12 from 14:00-14:25 PM ET. Investors attending can request one-on-one meetings through conference coordinators. CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting technologies using proprietary recombinant human collagen to address tissue repair and organ manufacturing.
CollPlant (NASDAQ: CLGN) announced its participation at the International Conference on Biofabrication in Tuscany, Italy, from September 25 to 28, 2022. The company will present on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" on September 28 during the symposium from 9:00 AM to 10:30 AM CET. CollPlant focuses on innovative solutions in tissue regeneration and organ manufacturing using its proprietary rhCollagen technology, and will feature an exhibition booth at the conference.
CollPlant Biotechnologies (Nasdaq: CLGN) announced participation in upcoming investor conferences. Deputy CEO and CFO Eran Rotem will engage with investors at the HC Wainwright 24th Annual Global Investment Conference on September 12-13 and the Alliance Global Partners MedTech Conference on September 21. CollPlant focuses on innovative collagen-based technologies for tissue regeneration and organ manufacturing. The company has also partnered with Allergan and 3D Systems to advance its product offerings in aesthetic and regenerative medicine.
CollPlant Biotechnologies (NASDAQ: CLGN) reported its Q2 2022 financial results, revealing a GAAP revenue of $66,000, down from $691,000 the previous year, primarily due to decreased BioInk and Vergenix product sales. The company reported a net loss of $4.3 million, or $0.39 per share. Notably, CollPlant is advancing its co-development agreement with AbbVie for dermal fillers and is on track for large animal studies of its 3D bioprinted regenerative breast implant. Cash and equivalents stood at $36 million as of June 30, 2022, reflecting a strong balance sheet.
CollPlant (NASDAQ: CLGN) is set to present at the TERMIS conference in Toronto, Canada from July 10-13, 2022. The company will showcase its revolutionary rhCollagen technology through two presentations: "RhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffolds for Regenerative Medicine" on July 13, and a poster on "Recombinant Human Collagen-Based Bioinks for Biofabrication Applications" on July 11. CollPlant focuses on advanced regenerative medicine, highlighting its innovative biomaterials aimed at tissue repair, bioprinting, and skin rejuvenation.
CollPlant (Nasdaq: CLGN) announced the initiation of a large animal study for its 3D bioprinted regenerative breast implants, targeting the $2.8 billion global breast implant market. This study aims to evaluate the implants' performance, including tissue regeneration and integration and is expected to conclude within six months. CollPlant's technology utilizes plant-derived rhCollagen, which aims to reduce safety issues linked to silicone implants. The company plans to follow this study with human trials, marking significant progress in their product development.
CollPlant Biotechnologies (NASDAQ: CLGN) reported updates on its strategic initiatives and Q1 2022 financial results. The company is advancing its collaboration with AbbVie to develop rhCollagen-based dermal fillers and is on track to initiate a large animal study for its 3D bioprinted breast implant program in Q2 2022. As of March 31, 2022, CollPlant had cash and equivalents of $41M. Q1 revenues declined to $66,000, down from $14.5M year-over-year, largely due to a $14M upfront payment from AbbVie in 2021. The GAAP net loss was $3.9M, or $0.36 per share.